Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIENCE II - Pilot: Stem Cell Therapy in Non-Ischemic Dilated Cardiomyopathy
NCT03797092Phase 2Unknown
- Sponsor
- Cell2Cure
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CSCC_ASC in dilated cardiomyopathy (DCM) and heart failure (HF) (2 arms), sponsored by Cell2Cure. Primary endpoint: Left ventricle end-systolic volume at 6 months. Status: unknown.
02
Drugs
CSCC_ASC
03
Conditions
dilated cardiomyopathy (DCM)heart failure (HF)
Beyond the preview
Go deeper on NCT03797092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797092.